Lineage Cell Therapeutics, Inc.
LCTX
$1.27
$0.0958.12%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 96.38% | 4.02% | 37.36% | 203.29% | -56.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.38% | 4.02% | 37.36% | 203.29% | -56.34% |
| Cost of Revenue | 8.00% | 0.57% | -14.06% | -17.93% | -27.20% |
| Gross Profit | 74.73% | 2.70% | 65.81% | 121.40% | -94.06% |
| SG&A Expenses | 4.52% | -2.80% | 480.61% | 9.13% | 2.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.91% | -1.21% | 62.15% | -4.18% | -11.81% |
| Operating Income | 15.80% | 2.34% | -80.44% | 42.73% | -16.78% |
| Income Before Tax | -425.97% | 36.83% | 31.06% | 58.07% | -10.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -425.97% | 36.83% | 31.06% | 58.07% | -10.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -869.23% | -75.00% | 62.30% | -168.75% | 150.00% |
| Net Income | -428.89% | 36.73% | 31.46% | 57.33% | -10.15% |
| EBIT | 15.80% | 2.34% | -80.44% | 42.73% | -16.78% |
| EBITDA | 16.70% | 2.24% | -86.64% | 43.35% | -17.94% |
| EPS Basic | -337.38% | 48.88% | 50.18% | 60.44% | 0.65% |
| Normalized Basic EPS | -125.79% | 48.88% | -86.96% | 59.76% | -1.60% |
| EPS Diluted | -337.38% | 48.88% | 50.18% | 60.44% | 0.65% |
| Normalized Diluted EPS | -125.79% | 48.88% | -86.96% | 59.76% | -1.60% |
| Average Basic Shares Outstanding | 20.94% | 23.59% | 37.24% | 7.99% | 10.68% |
| Average Diluted Shares Outstanding | 20.94% | 23.59% | 37.24% | 7.99% | 10.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |